{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:35:03Z","timestamp":1794900903662,"version":"4.9.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T00:00:00Z","timestamp":1537315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00432-018-2752-z","type":"journal-article","created":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T23:22:13Z","timestamp":1537312933000},"page":"717-723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group"],"prefix":"10.1007","volume":"145","author":[{"given":"Martin","family":"Fenner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Oing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Dieing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gauler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Oechsle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Lorch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hentrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Georg","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-3577","authenticated-orcid":false,"given":"Friedemann","family":"Honecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,19]]},"reference":[{"issue":"7","key":"2752_CR1","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/humrep\/det127","volume":"28","author":"KE Andreassen","year":"2013","unstructured":"Andreassen KE, Kristiansen W, Karlsson R, Aschim EL, Dahl O, Fossa SD, Adami HO, Wiklund F, Haugen TB, Grotmol T (2013) Genetic variation in AKT1, PTEN and the 8q24 locus, and the risk of testicular germ cell tumor. Hum Reprod 28(7):1995\u20132002. \n                    https:\/\/doi.org\/10.1093\/humrep\/det127","journal-title":"Hum Reprod"},{"issue":"6","key":"2752_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.cell.2004.12.040","volume":"120","author":"I Beuvink","year":"2005","unstructured":"Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O\u2019Reilly T, Natt F, Hall J, Lane HA, Thomas G (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120(6):747\u2013759. \n                    https:\/\/doi.org\/10.1016\/j.cell.2004.12.040","journal-title":"Cell"},{"issue":"4","key":"2752_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10637-009-9280-2","volume":"28","author":"DR Feldman","year":"2010","unstructured":"Feldman DR, Turkula S, Ginsberg MS, Ishill N, Patil S, Carousso M, Bosl GJ, Motzer RJ (2010) Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Investig New Drugs 28(4):523\u2013528. \n                    https:\/\/doi.org\/10.1007\/s10637-009-9280-2","journal-title":"Investig New Drugs"},{"issue":"11","key":"2752_CR4","first-page":"3783","volume":"31","author":"J Hennenlotter","year":"2011","unstructured":"Hennenlotter J, Amend B, Vogel U, Renninger M, Springer C, Kuehs U, Stenzl A, Bedke J (2011) Differential Akt signalling in non-seminomatous testicular germ cell tumors. Anticancer Res 31(11):3783\u20133788","journal-title":"Anticancer Res"},{"issue":"2","key":"2752_CR5","first-page":"594","volume":"15","author":"IGCCCG","year":"1997","unstructured":"IGCCCG (1997) International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. Int Germ Cell Cancer Collab Group J Clin Oncol 15(2):594\u2013603","journal-title":"Int Germ Cell Cancer Collab Group J Clin Oncol"},{"issue":"33","key":"2752_CR6","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1200\/JCO.2009.26.8128","volume":"28","author":"A Lorch","year":"2010","unstructured":"International Prognostic Factors Study Group, Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Flechon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK (2010) Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 28 (33):4906\u20134911. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.26.8128","journal-title":"J Clin Oncol"},{"issue":"1","key":"2752_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/andr.299","volume":"3","author":"C Jacobsen","year":"2015","unstructured":"Jacobsen C, Honecker F (2015) Cisplatin resistance in germ cell tumours: models and mechanisms. Andrology 3(1):111\u2013121. \n                    https:\/\/doi.org\/10.1111\/andr.299","journal-title":"Andrology"},{"issue":"3","key":"2752_CR8","doi-asserted-by":"publisher","first-page":"122e117","DOI":"10.1016\/j.urolonc.2015.10.010","volume":"34","author":"M Mego","year":"2016","unstructured":"Mego M, Svetlovska D, Miskovska V, Obertova J, Palacka P, Rajec J, Sycova-Mila Z, Chovanec M, Rejlekova K, Zuzak P, Ondrus D, Spanik S, Reckova M, Mardiak J (2016) Phase II study of everolimus in refractory testicular germ cell tumors. Urol Oncol 34(3):122e117\u2013122e122. \n                    https:\/\/doi.org\/10.1016\/j.urolonc.2015.10.010","journal-title":"Urol Oncol"},{"issue":"9637","key":"2752_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, RECORD-1 Study Group (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449\u2013456. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(08)61039-9","journal-title":"Lancet"},{"issue":"4","key":"2752_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.clgc.2016.03.020","volume":"14","author":"A Necchi","year":"2016","unstructured":"Necchi A, Anichini A, Raggi D, Giannatempo P, Magazzu D, Nicolai N, Colecchia M, Paolini B, Coradeschi E, Tassi E, Grazia G, Mortarini R, Calareso G, De Fato R, Togliardi E, Crippa F, Salvioni R, Valagussa P, Gianni AM (2016) Brentuximab vedotin in CD30-expressing germ cell tumors after chemotherapy failure. Clin Genitourin Cancer 14(4):261\u2013264 e264. \n                    https:\/\/doi.org\/10.1016\/j.clgc.2016.03.020","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"2752_CR11","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdx124","volume":"28","author":"A Necchi","year":"2017","unstructured":"Necchi A, Lo Vullo S, Giannatempo P, Raggi D, Calareso G, Togliardi E, Crippa F, Pennati M, Zaffaroni N, Perrone F, Busico A, Colecchia M, Nicolai N, Mariani L, Salvioni R (2017) Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. Ann Oncol 28(6):1346\u20131351. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx124","journal-title":"Ann Oncol"},{"issue":"12","key":"2752_CR12","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1093\/annonc\/mdr026","volume":"22","author":"K Oechsle","year":"2011","unstructured":"Oechsle K, Honecker F, Cheng T, Mayer F, Czaykowski P, Winquist E, Wood L, Fenner M, Glaesener S, Hartmann JT, Chi K, Bokemeyer C, Kollmannsberger C (2011) Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group\/German Testicular Cancer Study Group cooperative study. Ann Oncol 22(12):2654\u20132660. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdr026","journal-title":"Ann Oncol"},{"issue":"9","key":"2752_CR13","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/13543784.2016.1195808","volume":"25","author":"C Oing","year":"2016","unstructured":"Oing C, Kollmannsberger C, Oechsle K, Bokemeyer C (2016) Investigational targeted therapies for the treatment of testicular germ cell tumors. Expert Opin Investig Drugs 25(9):1033\u20131043. \n                    https:\/\/doi.org\/10.1080\/13543784.2016.1195808","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"2752_CR14","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00345-016-1898-z","volume":"35","author":"C Oing","year":"2017","unstructured":"Oing C, Alsdorf WH, Von Amsberg G, Oechsle K, Bokemeyer C (2017) Platinum-refractory germ cell tumors: an update on current treatment options and developments. World J Urol 35(8):1167\u20131175. \n                    https:\/\/doi.org\/10.1007\/s00345-016-1898-z","journal-title":"World J Urol"},{"issue":"2","key":"2752_CR15","first-page":"1091","volume":"8","author":"NQ Yang","year":"2016","unstructured":"Yang NQ, Luo XJ, Zhang J, Wang GM, Guo JM (2016) Crosstalk between Meg3 and miR-1297 regulates growth of testicular germ cell tumor through PTEN\/PI3K\/AKT pathway. Am J Transl Res 8(2):1091\u20131099","journal-title":"Am J Transl Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-018-2752-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2752-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2752-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T19:09:39Z","timestamp":1568833779000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-018-2752-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,19]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["2752"],"URL":"https:\/\/doi.org\/10.1007\/s00432-018-2752-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,19]]},"assertion":[{"value":"13 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AD: honoraria for speaking at symposia by Novartis. MH: financial support by Novartis for attending symposia. CB: honoraria for speaking at symposia and refunding of travel costs by Novartis. The remaining authors (MF, CO, KO, TG, GK, FH) declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The RADIT trial was approved by the Ethics Committee of the Hannover Medical School and the institutional review boards of all participating centers. The clinical trial was conducted in accordance with the ethical principles originating from the 1964 Declaration of Helsinki and its later amendments, consistent with Good Clinical Practice (GCP) and the applicable laws and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}